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Three human cell lines of astrocytic origin were evaluated for expression of a human T-lymphocyte surface 
glycoprotein, T4, which also serves as a cellular receptor for the human immunodeficiency virus (AIDS vi- 
rus, HIV). T4 antigen was detected on the cell surface of 2 of these cell lines using monoclonal OKT-4 anti- 
body and flow cytometry. Gene transcripts encoding the T4 molecule were detected by a ribonuclease pro- 
tection assay in surface TCpositive and -negative cells. Our results suggest hat astrocytes may serve as tar- 
gets for HIV infection in the brain. 
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1. INTRODUCTION 
Human immunodeficiency virus, the etiologic 
agent of AIDS (reviews [l,;?]), is the first animal 
retrovirus for which a cellular receptor has been 
identified. This receptor is a 62 kDa polypeptide 
which is expressed on human helper/inducer T 
lymphocytes and is known as the T4, or 
CD4/Leu3, antigen [3-51. The cytopathic interac- 
tion of HIV with T4+ lymphocytes is thought to be 
responsible for the depletion of helper/inducer T 
cells observed in AIDS patients f6], which is 
theorised to lead to the immune defects that are 
associated with this disease. The T4 antigen is also 
expressed by cells of the mononuclear phagocyte 
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series [7], but has not been reported to be present 
on non-hematopoietic ells. 
Whereas severe immunodeficiency is the most 
dramatic feature of AIDS 11,2,6], up to 75% of 
AIDS patients also develop unexpl~ned pro- 
gressive neurological disorders [S]. HIV has been 
isolated from cerebrospinal fluid of AIDS patients 
[9] and detected in brain tissue by hybridisation in 
situ [lo], indicating that this virus infects the cen- 
tral nervous system (CNS). Indeed, HIV has been 
demonstrated in macrophages in the brain 11 l] as 
well as in endothelial cells 1121 and possibly also 
astrocytes [13]. This raises the possibility that 
human brain cells, other than invading 
hematopoietic ells, may display the HIV receptor 
(T4 molecule), thereby providing a basis for HIV 
ne~otropism. Interestingly, both T4 and its 
murine homolog, L3T4, have been recently 
reported to be expressed at the RNA level in 
human and mouse brain, respectively [14,15]. 
However, neither report demonstrated the produc- 
tion of the corresponding proteins, nor were the 
cell type(s) encoding these mRNAs resolved. 
Here, we demonstrate the cell surface expression 
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of the T4 molecule and describe the detection of an 
RNA species encoding T4 in well-characterised 
human brainderived cell lines of astrocytic 
lineage. 
2. MATERIALS AND METHODS 
2.1. Cell lines 
Human brain tumor-delved cell lines U-25 I MG 
[f&17], U-343aMG and U-373MG fl5] were ob- 
tained from D.D. Signer, B. Westermark and 
American Type Culture Collection (ATCC, 
Rockville, MD), respectively. The T4+ cell line of 
human T cell leukemia origin, CEM (181, was ob- 
tained from L. Montagnier. 
2.2. hmunocytochernicai detection of GFAP 
GFAP was identified immunocytochemically by 
the avidin-biotin-peroxidase complex (ABC) 
method (Vector Laboratories) using monoclonal 
antibodies. Reagents were obtained from Boeh- 
ringer Ma~~~eirn (GFAP-specific monoclonal an- 
tibody G-A-5) and D.D. Bigner (GFAP-specific 
monoclonal antibody lB4), and were used at 
5-10 pg/ml. 
expression 
Levels of T4 receptor RNA were determined by 
ribonuclease protection using the T4 RNA probe 
as illustrated in fig.lB. The T4 RNA probe was 
derived by subcloning, in reverse orientation, a 
600 bp .&&RI&XI fragment of the T4 receptor 
cDNA ]19] into the transcription plasmid pGEM3 
(Promega Biotec, Inc.). r2P-1abelled single- 
stranded antisense probe was generated using the 
Sp6 promoter of the EcoRI linearised template in 
the presence of 1OpM t3’P]CTP (600 &i/mM) 
and excess (1 mM) cold ATP, GTP and UTP. 
105 cpm of probe was hybridised for I2 h at 42°C 
with 10 pug of total cellular RNA (extracted by the 
guanidinium isothiocyanate method [20]) or 20 pg 
tRNA in 30~1 of a solution containing 80% for- 
mamide, 400 mM NaCl, 20 mM Tris-HCl (pH 7-5) 
and I mM EDTA at 452°C for I2 h. The 
hybridisation was terminated by the addition of 
300,ul of 300 mM NaCl, 10 mM Tris, 1 mM 
EDTA containing 5 pg/ml RNase Tl and 20 pg/ml 
RNase A (Boehringer Mannbeim). Digestion of 
unhybridised probe proceeded at 22°C for 1 h, 
after which 20 pl of 10% SDS and 15 pl of pro- 
teinase K (10 mg/ml) were added for 15 min at 
37% The samples were extracted once with 
phenol, once with chlorofo~* and the RNA~RNA 
hybrids were precipitated with ethanol in the 
presence of 2Opg of carrier tRNA. The 
precipitated sample pellets were dissolved in 10 pl 
of formamide loading buffer (95% formamide, 
10 mM EDTA, 0.05% bromophenol blue, 0.05% 
xylene cyanof). The samples were el~rophor~d 
on denaturing 7 M urea/Y% polyacrylamide gels, 
dried and subjected to autoradiography. End- 
labelled M&I-digested pBR322 DNA served as 
molecular mass markers. 
2.4, De&&ion of ceil sqface T4 antigen 
expressim 
The 0KT4 surface marker was detected using a 
monoclonal antibody purchased from Ortho 
Diagnostic Systems, using an Ortho System 5OH 
c~o~uorog~ph (FACS). 
3. RESULTS 
For the purpose of this study, it was important 
to confirm that the three cell lines used, all 
originally derived from brain tumors [l&17], still 
expressed characteristics indicative of their ner- 
vous system origin and that they were free of any 
monocyte or T-lymphocyte contamination. Im- 
munocytochemical staining for the astrocyte- 
specific antigen, GFAP [Zl], revealed that approx. 
99% of the U-251MG and U-343aMG ceils ex- 
Fig. I. Immunocytochemical staining far GFAP using 
tnonoclonal antibody l&4 on the U-373MG cell line. 
M~~~~~~ion, x 3200 
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pressed this protein. Typical GFAP staining is il- and flow cytometry. As shown in fig.2, the 
lustrated in fig.1. Thus, the overwhelming U-343aMG and U-373MG, but not U-25lMG 
majority of these cells were astrocytic in origin. cells, clearly exhibited detectable levels of OKT4 
The proportion of the U-373MG cells that stained binding. The proportion of glial cells showing 
for GFAP was lower, about 90%. However, the T4-specific fluorescence and the mean fluorescence 
cells neither bound OKMl, 0KM3 antibodies (as intensity (fig.%B,D) were lower than those ob- 
detected by flow cytometry), nor did they exhibit served with control T4+ CEM cells (fig,2F), in- 
T cell receptor gene rearrangement or CT/7 gene ex- dicating a lower density of the T4 receptor on 
pression (not shown), indicating a lack of con- astrocytes as compared to a T-lymphatic cell 
tamination by known HIV-host cells. line. 
We next analysed the cells for surface T4 recep- 
tor expression using monoclonal 0KT4 antibody 
Since flow cytometric analysis of surface recep- 
tors in cells grown in monolayer cultures is often 
Green Fluorescence Intensity 
Fig.2. Flow cytometric analysis of cell surface T4 expression by: (B) U-373MG (33.7%); (D) U-343aMG (11.1%); (E) 
U-251MG (0.6%); (F) CEM (94.1%) cells. Numbers in parentheses represent the proportion of cells exhibiting 
T4-specific fluorescence, which was calculated by subtraction of background fluorescence from that observed with anti- 
T4 antibodies. Control staining with FITC alone is illustrated for (A) U-373MG and (C) U-343aMG celis. 
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associated with a significant background 
fluorescence (cf. fig.2A,C), we wished to confirm 
whether the positive fluorescence observed with 
anti-T4 antibodies indeed represented expression 
of the T4 gene. RNAs isolated from surface T4+ 
and T4- U-373MG and U-251MG cells, respective- 
ly, were therefore analysed for the presence of T4 
gene transcripts using human T4 cDNA probe [ 191 
and RNase protection assay. The results of this 
analysis are presented in fig.3. The two human 
astrocytic cell lines tested clearly contained 
mRNAs specific for the T4 gene. The presence of 
T4 mRNA in the surface T4- line U-25lMG is par- 
ticularly noteworthy because it indicates the limita- 
tion of flow c~ometry as a method of detecting 
low-density surface antigens. As expected, the T4+ 
lymphocytic cell line, CEM [18] expressed high 
levels of T4 gene transcripts. The relative levels of 
Tcspecific mRNA in glial cells were much lower 
(20-30 x) than in T-lymphoid cell lines. At this 
stage, it is unclear whether that reflected a lower 
expression of T4 gene per cell, or the fact that only 
a subpopulation of cells expressed the gene. 
4. DISCUSSION 
This is the first demonstration that well 
characterised cell lines derived from human brain, 
in this case GFAP-positive and therefore astrocytic 
in origin, also express the gene encoding the T4 
molecule - an antigen normally expected to be 
found on helper/inducer T lymphocytes. This 
observation is not entirely surprising. Since the 
original report of a shared antigen on murine lyrn- 
phocytes and brain cells 1221, several investigators 
have reported the existence of shared brain- 
lymphoid antigens, including Thy-l [23] and OX-2 
[24]. Furthermore, during the preparation of this 
work, Maddon et al. reported the detection of T4 
mRNA in human cerebral cortex, although the 
brain cell type(s) that express the T4 gene was not 
specified [14]. Our results clearly indicate that 
brain-derived cells, such as astrocytes, rather than 
rare invading hematopoietic ells, may be responsi- 
ble for the observed expression of the T4 molecule 
in human brain. Moreover, we demonstrate that 
the T4 gene is not only expressed at the mRNA 
level, but is also present on the astrocyte surface as 
an antigenically-recognisable T4 molecule (fig.2). 
This finding may have implications with regard to 
the possible functional signi~cance of T4 antigens 
in human brain, particularly in view of the 
reported interaction between Class II HLA 
molecules and the T4 molecule [25]. Such an in- 
teraction may, for example, participate in the 
transduction of a signal required for B cell activa- 
tion 1251, leading to ,possible autoimmune events. 
The observation that the T4 gene is expressed in 
cells of astrocytic origin, and perhaps other non- 
hematopoietic cells in the brain, may have 
relevance to the pathogenesis of AIDS-related 
brain disease. Although HIV can undoubtedly in- 
fect the human brain 19,101, the HIV-susceptible 
cell type(s) in this organ is unknown. HIV has been 
convincingly demonstrated in macrophages in the 
brain [l 11, but these cells could become infected in 
the peripheral circulatory system [26,27] and 
migrate across the brain-blood barrier. Our 
demonstration of the presence of the T4 molecule 
(HIV receptor) on astrocytes may thus provide an 
explanation for the presumed neurotropism of 
HIV and encourage studies on the infectivity of 
brain cells by this virus. These experiments are in 
progress in our laboratory. 
-W-*-W 
600 bp. 
T-4 prabe 
Fig.3. Detection of T4 gene transcripts in the indicated 
cell lines by an RNase protection assay. 
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